This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.
The aim of this study was to investigate the influence of statins on the secretion of angiogenesis mediators by the peripheral blood mononuclear cells (PBMCs) derived from patients suffering from type 2 diabetes. The study group comprised 30 participants and included: 10 statin-treated patients with diabetes, 10 statin-free diabetic subjects, and 10 statin-free non-diabetic individuals. PBMCs isolated from the blood were cultured in vitro in standard conditions and in an environment mimicking hyperglycemia. Culture supernatants were evaluated for VEGF, MCP-1, Il-10, and Il-12 by flow cytometry using commercial BDTM. Cytometric Bead Array tests. The secretion of VEGF, MCP-1 and Il-12 by PBMCs, cultured both in standard and hyperglycemic conditions, was significantly lower in the statin-treated patients with type 2 diabetes in comparison with the statin-free diabetic patients. Conversely, the secretion of Il-10 was higher in the statin-treated than in the statin-free diabetic patients. VEGF, MCP-1 and Il-12 levels in PBMCs supernatants from the glucose-containing medium were higher than those from the standard medium in each of the diabetic groups. The results of the study suggest that statins in low doses exhibit an antiangiogenic activity, reducing the secretion of potent proangiogenic factors, such as VEGF and MCP-1, and increasing the secretion of antiangiogenic Il-10 by PBMCs, also under hyperglycemic conditions characteristic for type 2 diabetes.
of continuous glucose monitoring on fear of hypoglycemia 1 compared with controls, without acknowledging that baseline fear of hypoglycemia was higher in the intervention group.Furthermore, 3 studies were excluded from the review due to the lack of a control group, yet one of these was a randomized, controlled, crossover study (Hommel et al; Acta Diabetol, 2014), which indicates the presence of a control group. The other 2 studies were prospective, observational studies with a total of 694 adult participants (Charleer et al; J Clin Endocrinol Metab, 2018 and Nørgaard et al; Diabetes Technol Ther, 2013). The authors included a cross -sectional study, 2 yet decided to exclude these 2 prospective studies that could add real -life insights on the temporality of the association observed between technology use and the outcomes.In conclusion, while Kłak et al 1 presented interesting results summarizing some of the literature data on the important topic of diabetes technologies and fear of hypoglycemia, certain methodological aspects might need further consideration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.